SAN DIEGO--(BUSINESS WIRE)--Jan. 11, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced Jim Daly has joined its Board of Directors.
Mr. Daly is a biopharmaceutical executive with 30 years of experience
leading U.S. and global businesses.
“Jim brings extensive commercial experience to our Board as we continue
our transition to an integrated pharmaceutical company,” said Leslie L.
Iversen, Ph.D., Chairman of ACADIA’s Board of Directors. “Over the
course of his career, Jim has successfully launched and commercialized
major products in multiple therapeutic areas and built market-leading
global franchises. His deep knowledge and expertise are welcome as we
deliver on our vision of building a leading CNS company dedicated to
improving the lives of patients through innovative medicines.”
Mr. Daly previously served as Executive Vice President and Chief
Commercial Officer at Incyte Corporation from 2012 to 2015. During his
tenure, he was instrumental in re-accelerating the launch of Jakafi®
and driving sustained growth. Prior to joining Incyte, Mr. Daly worked
for Amgen, Inc. for ten years, holding multiple leadership positions. In
his last role, Mr. Daly served as Senior Vice President, North America
Commercial Operations, Global Marketing and Commercial Development.
Previously, he served as Vice President and General Manager of Amgen’s
Oncology Business Unit. His teams at Amgen were responsible for the
successful launch of many products, including Aranesp®,
Neulasta®, Vectibix®, Nplate®, Xgeva®
Previously, Mr. Daly spent over 16 years with Glaxo
Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing
responsibility, including Senior Vice President, General Manager,
Respiratory and Anti-Infective Business Unit, and led the U.S. launch of
Advair®. He currently serves on the Board of Directors of
Chimerix Inc. Mr. Daly earned his B.S. in Pharmacy and M.B.A. from the
University at Buffalo, The State University of New York.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has a pipeline of product
candidates led by NUPLAZID™ (pimavanserin), for which we have submitted
a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA
and which has the potential to be the first drug approved in the United
States for this condition. The FDA has classified the NUPLAZID NDA as
having Priority Review status. Pimavanserin is also in Phase II
development for Alzheimer’s disease psychosis and has successfully
completed a Phase II trial in schizophrenia. ACADIA also has
clinical-stage programs for glaucoma and, in collaboration with
Allergan, Inc., for chronic pain. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the potential for NUPLAZID
(pimavanserin) to be the first drug approved in the United States for
Parkinson’s disease psychosis (PDP) and the potential timing of such
approval, if approved at all, by the FDA; the benefits to ACADIA of Mr.
Daly joining its Board of Directors; the progress, timing and results of
ACADIA’s drug discovery and development programs, either alone or with a
partner, including the progress and expected timing of clinical trials;
and the benefits to be derived from ACADIA’s product candidates,
including pimavanserin. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including
the risks and uncertainties inherent in drug discovery, development,
approval and commercialization, and collaborations with others, and the
fact that past results of clinical trials and past regulatory decisions
may not be indicative of future trial results or future regulatory
decisions, respectively. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year ended
December 31, 2014 as well as ACADIA’s subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160111005457/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, 858-558-2871
of Investor Relations